SONN - Sonnet BioTherapeutics Holdings, Inc.

1.26
-1.840   -146.032%

Share volume: 10,456,154
Last Updated: 12-02-2025
Pharmaceutical Products/Pharmaceutical Preparations: 3.72%

PREVIOUS CLOSE
CHG
CHG%
$3.10
-1.84
-0.59%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
43%
Profitability 35%
Dept financing 42%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
-55.79%
1 Year
-13.70%
2 Year
-33.68%
Key data
Stock price
$1.26
P/E Ratio 
N/A
DAY RANGE
$1.26 - $3.23
EPS 
-$6.53
52 WEEK RANGE
$1.08 - $19.30
52 WEEK CHANGE
-$12.50
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
-0.28
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Pankaj Mohan
Region: US
Website: sonnetbio.com
Employees: 10
IPO year: 2006
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Sonnet BioTherapeutics Holdings, Inc. develops platform for biologic medicines of single or bispecific action. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer.

Recent news